Your browser doesn't support javascript.
Clinical, laboratory, and temporal predictors of neutralizing antibodies against SARS-CoV-2 among COVID-19 convalescent plasma donor candidates.
Boonyaratanakornkit, Jim; Morishima, Chihiro; Selke, Stacy; Zamora, Danniel; McGuffin, Sarah; Shapiro, Adrienne E; Campbell, Victoria L; McClurkan, Christopher L; Jing, Lichen; Gross, Robin; Liang, Janie; Postnikova, Elena; Mazur, Steven; Lukin, Vladimir V; Chaudhary, Anu; Das, Marie K; Fink, Susan L; Bryan, Andrew; Greninger, Alex L; Jerome, Keith R; Holbrook, Michael R; Gernsheimer, Terry B; Wener, Mark H; Wald, Anna; Koelle, David M.
  • Boonyaratanakornkit J; Department of Medicine, University of Washington, Seattle, Washington, USA.
  • Morishima C; Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
  • Selke S; Seattle Cancer Care Alliance, Seattle, Washington, USA.
  • Zamora D; Department of Laboratory Medicine and Pathology, and.
  • McGuffin S; Department of Laboratory Medicine and Pathology, and.
  • Shapiro AE; Department of Medicine, University of Washington, Seattle, Washington, USA.
  • Campbell VL; Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
  • McClurkan CL; Department of Medicine, University of Washington, Seattle, Washington, USA.
  • Jing L; Department of Medicine, University of Washington, Seattle, Washington, USA.
  • Gross R; Department of Global Health, University of Washington, Seattle, Washington, USA.
  • Liang J; Department of Medicine, University of Washington, Seattle, Washington, USA.
  • Postnikova E; Department of Medicine, University of Washington, Seattle, Washington, USA.
  • Mazur S; Department of Medicine, University of Washington, Seattle, Washington, USA.
  • Lukin VV; Integrated Research Facility, Division of Clinical Research, National Institute of Allergy and Infectious Diseases (NIAID), NIH, Frederick, Maryland, USA.
  • Chaudhary A; Integrated Research Facility, Division of Clinical Research, National Institute of Allergy and Infectious Diseases (NIAID), NIH, Frederick, Maryland, USA.
  • Das MK; Integrated Research Facility, Division of Clinical Research, National Institute of Allergy and Infectious Diseases (NIAID), NIH, Frederick, Maryland, USA.
  • Fink SL; Integrated Research Facility, Division of Clinical Research, National Institute of Allergy and Infectious Diseases (NIAID), NIH, Frederick, Maryland, USA.
  • Bryan A; Kearney, Chicago, Illinois, USA.
  • Greninger AL; Department of Laboratory Medicine and Pathology, and.
  • Jerome KR; Department of Laboratory Medicine and Pathology, and.
  • Holbrook MR; Department of Laboratory Medicine and Pathology, and.
  • Gernsheimer TB; Department of Laboratory Medicine and Pathology, and.
  • Wener MH; Department of Laboratory Medicine and Pathology, and.
  • Wald A; Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
  • Koelle DM; Department of Laboratory Medicine and Pathology, and.
J Clin Invest ; 131(3)2021 02 01.
Article in English | MEDLINE | ID: covidwho-1124908
ABSTRACT
BACKGROUNDSARS-CoV-2-specific antibodies may protect from reinfection and disease, providing rationale for administration of plasma containing SARS-CoV-2-neutralizing antibodies (nAbs) as a treatment for COVID-19. Clinical factors and laboratory assays to streamline plasma donor selection, and the durability of nAb responses, are incompletely understood.METHODSPotential convalescent plasma donors with virologically documented SARS-CoV-2 infection were tested for serum IgG against SARS-CoV-2 spike protein S1 domain and against nucleoprotein (NP), and for nAb.RESULTSAmong 250 consecutive persons, including 27 (11%) requiring hospitalization, who were studied a median of 67 days since symptom onset, 97% were seropositive on 1 or more assays. Sixty percent of donors had nAb titers ≥180. Correlates of higher nAb titers included older age (adjusted OR [AOR] 1.03 per year of age, 95% CI 1.00-1.06), male sex (AOR 2.08, 95% CI 1.13-3.82), fever during illness (AOR 2.73, 95% CI 1.25-5.97), and disease severity represented by hospitalization (AOR 6.59, 95% CI 1.32-32.96). Receiver operating characteristic analyses of anti-S1 and anti-NP antibody results yielded cutoffs that corresponded well with nAb titers, with the anti-S1 assay being slightly more predictive. nAb titers declined in 37 of 41 paired specimens collected a median of 98 days (range 77-120) apart (P < 0.001). Seven individuals (2.8%) were persistently seronegative and lacked T cell responses.CONCLUSIONnAb titers correlated with COVID-19 severity, age, and sex. SARS-CoV-2 IgG results can serve as useful surrogates for nAb testing. Functional nAb levels declined, and a small proportion of convalescent individuals lacked adaptive immune responses.FUNDINGThe project was supported by the Frederick National Laboratory for Cancer Research with support from the NIAID under contract number 75N91019D00024, and was supported by the Fred Hutchinson Joel Meyers Endowment, Fast-Grants, a New Investigator award from the American Society for Transplantation and Cellular Therapy, and NIH contracts 75N93019C0063, 75N91019D00024, and HHSN272201800013C, and NIH grants T32-AI118690, T32-AI007044, K08-AI119142, and K23-AI140918.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Blood Donors / Immunoglobulin G / Antibodies, Neutralizing / SARS-CoV-2 / COVID-19 / Antibodies, Viral Type of study: Prognostic study Topics: Long Covid Limits: Adult / Aged / Female / Humans / Male / Middle aged Language: English Year: 2021 Document Type: Article Affiliation country: Jci144930

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Blood Donors / Immunoglobulin G / Antibodies, Neutralizing / SARS-CoV-2 / COVID-19 / Antibodies, Viral Type of study: Prognostic study Topics: Long Covid Limits: Adult / Aged / Female / Humans / Male / Middle aged Language: English Year: 2021 Document Type: Article Affiliation country: Jci144930